<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors - Matino, D - 2015 | Cochrane Library</title> <meta content="Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors - Matino, D - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004449.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors - Matino, D - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004449.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004449.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors" name="citation_title"/> <meta content="Davide Matino" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Michael Makris" name="citation_author"/> <meta content="University of Sheffield" name="citation_author_institution"/> <meta content="Kerry Dwan" name="citation_author"/> <meta content="Cochrane Central Executive" name="citation_author_institution"/> <meta content="Roberto D'Amico" name="citation_author"/> <meta content="University of Modena and Reggio Emilia" name="citation_author_institution"/> <meta content="Alfonso Iorio" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="iorioa@mcmaster.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD004449.pub4" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/12/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004449.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004449.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004449.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Blood Coagulation Factors [*therapeutic use]; Factor VIII [immunology, therapeutic use]; Factor VIIa [*therapeutic use]; Hemophilia A [blood, *drug therapy]; Hemophilia B [blood, *drug therapy]; Hemorrhage [*drug therapy]; Randomized Controlled Trials as Topic; Recombinant Proteins [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004449.pub4&amp;doi=10.1002/14651858.CD004449.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004449\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004449\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004449.pub4",title:"Recombinant factor VIIa concentrate versus plasma\\u2010derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors",firstPublishedDate:"Dec 16, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004449.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004449.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004449.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004449.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004449.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004449.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004449.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004449.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004449.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004449.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2333 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004449.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/table_n/CD004449StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/table_n/CD004449StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information#CD004449-cr-0002">Davide Matino</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information#CD004449-cr-0003">Michael Makris</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information#CD004449-cr-0004">Kerry Dwan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information#CD004449-cr-0005">Roberto D'Amico</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information#CD004449-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Alfonso Iorio</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information/en#CD004449-sec-0089">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 December 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004449.pub4">https://doi.org/10.1002/14651858.CD004449.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004449-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004449-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004449-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004449-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004449-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004449-abs-0001" lang="en"> <section id="CD004449-sec-0001"> <h3 class="title" id="CD004449-sec-0001">Background</h3> <p>In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti‐factor VIII antibodies, known as 'inhibitors'. Drugs insensitive to such antibodies, either recombinant or plasma‐derived, are called factor VIII 'by‐passing' agents and used for treatment of bleeding in people with inhibitors. </p> </section> <section id="CD004449-sec-0002"> <h3 class="title" id="CD004449-sec-0002">Objectives</h3> <p>To determine the clinical effectiveness of recombinant factor VIIa concentrate compared to plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. </p> </section> <section id="CD004449-sec-0003"> <h3 class="title" id="CD004449-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Coagulopathies Trials Register which comprises references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. </p> <p>Date of the most recent search of the Group's Coagulopathies Trials Register: 23 September 2015. </p> </section> <section id="CD004449-sec-0004"> <h3 class="title" id="CD004449-sec-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised controlled clinical trials comparing recombinant factor VIIa concentrate to human plasma‐derived concentrates (high‐dose human or recombinant factor VIII or factor IX concentrate; non‐activated prothrombin complex concentrates; activated prothrombin complex concentrates) in people with haemophilia. Comparisons with animal‐derived products were excluded. </p> </section> <section id="CD004449-sec-0005"> <h3 class="title" id="CD004449-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed the trials (eligibility and risk of bias) and extracted data. No combined meta‐analyses were performed due to the unavailability of outcomes and comparisons common to the included trials. </p> </section> <section id="CD004449-sec-0006"> <h3 class="title" id="CD004449-sec-0006">Main results</h3> <p>A total of 15 trials were identified, two of which (with data for a total of 69 participants) were eligible for analysis. Both trials showed methodological flaws and did not show superiority of one treatment over the other. Both the treatments showed that recombinant factor VIIa and activated prothrombin complex concentrate appeared to have a similar haemostatic effect in both trials, without increasing thromboembolic risk. </p> </section> <section id="CD004449-sec-0007"> <h3 class="title" id="CD004449-sec-0007">Authors' conclusions</h3> <p>Based on the separate analysis of the two available randomised trials, recombinant factor VIIa and activated prothrombin complex concentrate were found to be similar in efficacy and safety. However, there is a need for further, well‐designed, adequately‐powered, randomised controlled trials to assess the relative benefits and risks of using recombinant factor VIIa compared to human plasma‐derived concentrates in people with haemophilia with inhibitors. It is advisable that researchers in the field define commonly agreed objective outcome measures in order to enable the pooling of their results, thus increasing the power of comparisons. To date, data could not be combined in a formal meta‐analysis. For the same reason reporting concordant and discordant pairs in cross‐over trials is recommended. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004449-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004449-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004449-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004449-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004449-abs-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004449-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004449-abs-0002" lang="en"> <h3>Recombinant (non‐human) factor VIIa clotting factor concentrates versus plasma concentrates for acute bleeds in people with haemophilia and inhibitors </h3> <p><b>Review question</b> </p> <p>We wanted to find evidence on the effectiveness of recombinant factor VIIa (containing no human proteins) as compared to concentrates derived from plasma for treating acute bleeding episodes in people with haemophilia with inhibitors. </p> <p><b>Background</b> </p> <p>Haemophilia is an inherited bleeding disorder caused by a lack of a clotting factor and is characterised by bleeding into the joints. It is treated by injecting a drug containing the missing clotting factor into veins. In some individuals with haemophilia, this factor is seen by the body as a foreign protein when it is injected and the body produces an antibody (inhibitor) that destroys the factor. In this way these people become resistant to treatment. Once someone with haemophilia develops an inhibitor, they are treated to remove the antibody (immunotolerance induction) and for acute bleeding episodes. Treatment for bleeding episodes is with one of two available bypassing agents, recombinant activated factor VIIa (Novoseven<sup>®</sup>) or human activated prothrombin complex concentrate (FEIBA<sup>®</sup>). It is not known if one of these products is better than the other. We searched for trials comparing the effectiveness (time until bleeding stops, effect on joint motion, need for re‐treatment) and safety of Novoseven<sup>®</sup> and FEIBA<sup>®</sup> in people with haemophilia with inhibitors during episodes of acute bleeding. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 23 September 2015.</p> <p><b>Study characteristics</b> </p> <p>The review included two trials with 69 people (aged one to 55 years) with severe haemophilia with inhibitors<i>.</i> Both trials compared recombinant factor VIIa with activated prothrombin complex concentrate and people were selected for one treatment or the other randomly. </p> <p><b>Key results</b><br/> We found two clinical trials comparing Novoseven<sup>®</sup> and FEIBA<sup>®</sup>. The trials did not show a difference in how well the two products worked and both were tolerated equally well with no clotting complications. We conclude that both recombinant factor VIIa and plasma‐derived concentrates can be used to treat bleeds in people with haemophilia and inhibitors. </p> <p><b>Quality of the evidence</b> </p> <p>There were some major problems with regards to the way both trials were designed, in relation to knowing which treatment group each person was in (both before the trial was started and during) and also how missing results were handled. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004449-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004449-sec-0081"></div> <h3 class="title" id="CD004449-sec-0082">Implications for practice</h3> <section id="CD004449-sec-0082"> <p>Based on the separate analysis of the two available randomised trials, rFVIIa and aPCC were found to be similar in efficacy and in causing a low risk of thromboembolic complications. Both drugs can be administered as single intravenous bolus (270 mcg/kg of rFVIIa, 75 to 100 IU/kg of aPCC). Other non‐randomised evidence can be usefully taken into account in the choice of the more appropriate treatment in clinical practice. The choice between different regimens of rFVIIa is beyond the scope of this review, and should be mainly based on general considerations about the use of recombinant versus plasma‐derived concentrates in specific categories of people (i.e. children). </p> </section> <h3 class="title" id="CD004449-sec-0083">Implications for research</h3> <section id="CD004449-sec-0083"> <p>There is need for further well‐designed, adequately‐powered randomised controlled trials to assess the relative benefits and risks of using rFVIIa compared to human plasma‐derived concentrates in people with haemophilia with inhibitors. It is advisable that researchers in the field define commonly agreed objective outcome measures in order to enable easier pooling of their results thus increasing the power of comparisons. To the same, scope reporting concordant and discordant pairs in cross‐over trials would be recommended. Both tasks are difficult to pursue, but very relevant and should be sought in view of the high societal costs of treating people with haemophilia with inhibitors. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004449-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004449-sec-0022"></div> <section id="CD004449-sec-0023"> <h3 class="title" id="CD004449-sec-0023">Description of the condition</h3> <p>Haemophilia is an inherited disorder where affected individuals suffer from excessive bleeding. It is inherited as an X‐linked disorder, but in around a third of all cases no family history is present. People with haemophilia develop spontaneous bleeding into joints and suffer excessive bleeding after injury or surgery which can be hazardous unless appropriately managed in expert centres. Two main types are recognised due to either a deficiency of factor VIII (FVIII) (haemophilia A) or of factor IX (FIX) (haemophilia B). The prevalence is similar worldwide and for haemophilia A is 1 in 10,000 and for haemophilia B is 1 in 60,000 births (<a href="./references#CD004449-bbs2-0029" title="MannucciPM , TuddenhamEG . The hemophilias ‐ from royal genes to gene therapy. New England Journal of Medicine2001;344(23):1773‐9. ">Mannucci 2001</a>). </p> <p>The severity of the phenotype depends on the baseline concentration of the clotting factor. The severity of haemophilia has been defined by the International Society for Thrombosis and Haemostasis as: </p> <p> <ul id="CD004449-list-0001"> <li> <p>severe, where the factor is less than 0.01 units per millilitre (u/ml);</p> </li> <li> <p>moderate, where the factor ranges from 0.01 u/ml to less than 0.05 u/ml; and</p> </li> <li> <p>mild, where the factor is greater than 0.05 u/ml (<a href="./references#CD004449-bbs2-0034" title="WhiteGC2nd , RosendaalF , AledortLM , LusherJM , RothschildC , IngerslevJ , et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis2001;85(3):560. ">White 2001</a>). </p> </li> </ul> </p> <p>Spontaneous bleeding into joints is seen primarily in people with severe haemophilia.</p> </section> <section id="CD004449-sec-0024"> <h3 class="title" id="CD004449-sec-0024">Description of the intervention</h3> <p>The mainstay of treatment in bleeding disorders due to factor deficiency is the correction of the defect by the intravenous infusion of the appropriate clotting factor. For haemophilia, initially in the 1960s this consisted of the infusion of fresh frozen plasma (haemophilia A and haemophilia B) and cryoprecipitate (haemophilia A) and was followed in the 1970s by the introduction of FVIII (haemophilia A) or FIX (haemophilia B) concentrates. Over the last 30 years the purity of concentrates has increased; and since 1985 viral inactivation procedures were introduced to eliminated blood product‐transmitted infections such as HIV and hepatitis C (<a href="./references#CD004449-bbs2-0030" title="RizzaCR , SpoonerRJ , GiangrandePL , UK Haemophilia Centre Doctors' Organization (UKCDO). Treatment of haemophilia in the United Kingdom 1981‐1996. Haemophilia2001;7(4):349‐59. ">Rizza 2001</a>). At the beginning of the 1990s recombinant factor concentrates (that do not contain human proteins) were developed and these have entered clinical practice (<a href="./references#CD004449-bbs2-0033" title="United Kingdom Haemophilia Doctors'Organisation . Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia2003;9(1):1‐13. ">UKHCDO 2003</a>). </p> <p>In some people with haemophilia the administered factor is recognised as a foreign protein and anti‐FVIII or anti‐FIX antibodies are produced. These antibodies are referred to as inhibitors when they inhibit the activity of the administrated factor. The reported prevalence of inhibitors in haemophilia A varies enormously from 3.6% (<a href="./references#CD004449-bbs2-0035" title="YeeTT , PasiKJ , LilleyPA , LeeCA . Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964‐97. British Journal of Haematology1999;104(4):909‐14. ">Yee 1999</a>) to 32% (<a href="./references#CD004449-bbs2-0027" title="KreuzW , EttingshausenCE , ZyschkaA , OldenbergJ , SaguerIM , EhrenforthS , et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long‐term follow‐up comparing plasma‐derived and recombinant products. Seminars in Thrombosis and Hemostasis2002;28(3):285‐90. ">Kreuz 2002</a>). The incident rate of inhibitors is much lower in haemophilia B than in haemophilia A, but inhibitor treatment in haemophilia B is hampered by complications due to immuno‐complex mediated renal damage (<a href="./references#CD004449-bbs2-0021" title="EwensteinBM , TakemotoC , WarrierI , LusherJ , SaidiP , EiseleJ , et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood1997;89(3):1115‐6. ">Ewenstein 1997</a>). The risk of developing an inhibitor has been found to be associated with: the causative genetic defect (<a href="./references#CD004449-bbs2-0018" title="DimicheleD . Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia2002;8(3):280‐7. ">Dimichele 2002</a>), with gene deletions having the highest risk of developing an inhibitor (<a href="./references#CD004449-bbs2-0022" title="GoodeveAC , PeakeIR . The molecular basis of hemophilia a: genotype‐phenotype relationships and inhibitor development. Seminars in Thrombosis and Hemostasis2003;29(1):23‐30. ">Goodeve 2003</a>); ethnicity; family history of haemophilia with or without inhibitors; the length and intensity of exposure to factor concentrates; the age at first exposure; and the occurrence of a trigger event (i.e. bleeding, surgery or infections). Other reasons for the varying prevalence of inhibitors observed in different published reports may be the laboratory method for measuring the inhibitor as well as the frequency of inhibitor testing. The lower prevalence of gene deletions in haemophilia B partly explains the lower rate of inhibitor development (<a href="./references#CD004449-bbs2-0019" title="DiMicheleD . Inhibitor development in haemophilia B: an orphan disease in need of attention. British Journal of Haematology2007;138(3):305‐15. [DOI: 10.1111/j.1365‐2141.2007.06657.x] ">DiMichele 2007</a>). </p> <p>There are two key elements in the treatment of people with haemophilia with inhibitors. The first, which is addressed by this review, is the treatment of the individual to arrest the acute bleeding. The second element is treatment to eliminate the inhibitor (immune tolerance induction), which is the subject of another Cochrane review (<a href="./references#CD004449-bbs2-0016" title="AthaleAH , MarcucciM , IorioA . Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD010561.pub2] ">Athale 2014</a>). </p> </section> <section id="CD004449-sec-0025"> <h3 class="title" id="CD004449-sec-0025">How the intervention might work</h3> <p>The acute treatment of someone with haemophilia and an inhibitor depends on the level of the antibody or inhibitor that is measured <i>in vitro</i> and is quantified in Bethesda units. A Bethesda unit is a measure of inhibitor activity and is the amount of inhibitor that will inactivate 50% or 0.5 unit of a coagulation factor in an activated partial thromboplastin time (aPTT)‐based coagulation factor assay following a two‐hour incubation period in an imidazole buffer diluted sample. Although some people with haemophilia with low levels of inhibitor can be treated with standard concentrates, in practice most have inhibitors that destroy the infused FVIII or FIX and other products have been developed to treat these individuals. These are based on human plasma such as activated prothrombin complex concentrates (aPCC) (brands available are FEIBA<sup>®</sup> and Autoplex<sup>®</sup>) or non‐activated prothrombin complex concentrates (PCC) or animal plasma such as Hyate‐C<sup>®</sup> (FVIII prepared from porcine plasma, can be used in people with haemophilia with no antibodies to porcine FVIII) (<a href="./references#CD004449-bbs2-0023" title="HayCRM , BaglinTP , CollinsPW , HillFGH , KeelingDM . The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). British Journal of Haematology2000;111(1):78‐90. ">Hay 2000</a>). A more recent alternative approach has been the use of recombinant FVIIa concentrate (rFVIIa) (NovoSeven<sup>®</sup>), which was introduced early in the 1990s and shown to be highly effective but also associated with a relatively high cost (<a href="./references#CD004449-bbs2-0024" title="HednerU . Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Seminars in Thrombosis and Hemostasis2000;26(4):363‐6. ">Hedner 2000</a>). Mainly aPCC exerts its effect by providing activated factor IX and X, which are able to produce a significant amount of thrombin without any requirement for FVIII (<a href="./references#CD004449-bbs2-0031" title="ThomasT , WilliamsH , WilliamsY , HuntJ . FEIBA in haemophiliacs with factor VIII inhibitor. BMJ1977;1(6052):52. ">Thomas 1977</a>); noticeably, aPCC is not expected to be active in people with factor IX deficiency. At a pharmacological concentration, rFVII is able to directly activate thrombin when bound to tissue factor or to activate factor Xa on the surface of activated platelets (<a href="./references#CD004449-bbs2-0024" title="HednerU . Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Seminars in Thrombosis and Hemostasis2000;26(4):363‐6. ">Hedner 2000</a>). The difference in the mechanism of action of the two compounds makes it reasonable to switch the non‐responding individual from one treatment to the other, and to assess the efficacy and safety of the combination of the two drugs. </p> </section> <section id="CD004449-sec-0026"> <h3 class="title" id="CD004449-sec-0026">Why it is important to do this review</h3> <p>This review investigates which is the most effective treatment of acute bleeding in people with haemophilia with inhibitors. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004449-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004449-sec-0027"></div> <p>To determine the clinical effectiveness of rFVIIa in comparison to PCC or aPCC for treating acute bleeding episodes in people with haemophilia with inhibitors. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004449-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004449-sec-0028"></div> <section id="CD004449-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004449-sec-0030"> <h4 class="title">Types of studies</h4> <p>Randomised (RCTs) and quasi‐randomised controlled clinical trials.</p> </section> <section id="CD004449-sec-0031"> <h4 class="title">Types of participants</h4> <p>Children and adults with haemophilia, of all degrees of severity diagnosed by decreased blood levels of functional procoagulant FVIII or FIX and with FVIII or FIX inhibitors of any titre. </p> </section> <section id="CD004449-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Recombinant FVIIa concentrate (rFVIIa) compared to human plasma‐derived concentrates (high‐dose human or recombinant FVIII or FIX concentrate; PCCs; aPCC). Comparisons with animal‐derived products were excluded. </p> </section> <section id="CD004449-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD004449-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004449-list-0002"> <li> <p>Early cessation of bleeding measured by</p> <ol id="CD004449-list-0003"> <li> <p>changes on any subjective or objective pain and mobility scale or</p> </li> <li> <p>by the volume of haematoma assessed radiologically at any point in the first 48 hours</p> </li> </ol> </li> </ol> </p> </section> <section id="CD004449-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD004449-list-0004"> <li> <p>Number of participants requiring additional or alternative treatment</p> </li> <li> <p>Number of participants with adverse effects (thromboses; allergic reactions)</p> </li> <li> <p>Correction of abnormal haemostatic laboratory test results</p> </li> </ol> </p> </section> </section> </section> <section id="CD004449-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <p>No restrictions based on dates, language or publication status were imposed.</p> <section id="CD004449-sec-0037"> <h4 class="title">Electronic searches</h4> <p>Relevant trials were searched for on the Group's Coagulopathies Trials Register using the terms: (haemophilia A AND factor VIIa) OR (haemophilia B AND factor VIIa) OR (haemophilia general AND (recombinant factor VIIa OR factor VIIa)) </p> <p>The coagulopathies register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <i>The Cochrane Library</i> ), weekly searches of MEDLINE and the prospective handsearching of one journal ‐ <i>Haemophilia</i>. Unpublished work is identified by searching the abstract books of four major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; and the Congress of the World Federation of Haemophilia. For full details of all searching activities for the register, please see the relevant section of the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html" target="_blank">Cochrane Cystic Fibrosis and Genetic Disorders Group Module</a>. </p> <p>Date of the most recent search of the Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register: 23 September 2015. </p> </section> </section> <section id="CD004449-sec-0038"> <h3 class="title" id="CD004449-sec-0038">Data collection and analysis</h3> <section id="CD004449-sec-0039"> <h4 class="title">Selection of studies</h4> <p>In the 2010 update, two trials were found to be eligible for inclusion (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>; <a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). Additional data were obtained from trial authors for the 2015 update and included in the review (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>; <a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). </p> <p>For the references found when updating the review after October 2007, two authors (AI, DM) independently selected the trials to be included in the review. When disagreement arose on the suitability of a trial for inclusion in the review or on its quality, we attempted to reach a consensus by discussion. </p> </section> <section id="CD004449-sec-0040"> <h4 class="title">Data extraction and management</h4> <p>Two authors (AI, DM) independently extracted data using standard data acquisition forms. When disagreement arose on the suitability of a trial for inclusion in the review or on its quality, we reached a consensus by discussion. </p> </section> <section id="CD004449-sec-0041"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (AI, DM) assessed the risk of bias of each trial. In particular, they examined details of the randomisation method, whether the trial was blinded, whether intention‐to‐treat analyses were possible from the available data and if the number of participants lost to follow up or subsequently excluded from the study was recorded. When disagreement arose on the suitability of a trial for inclusion in the review or on its quality, we reached a consensus by discussion. </p> <section id="CD004449-sec-0042"> <h5 class="title">Randomisation method</h5> <p>We assessed the risk of bias from the randomisation sequence as low if this was generated using, e.g. a computer or a random numbers table; we assessed the risk of bias as unclear if the methods were not described; and we assessed the risk of bias as high if a non‐random approach was used, e.g. date of birth, clinical record number. </p> </section> <section id="CD004449-sec-0043"> <h5 class="title">Concealment of allocation</h5> <p>We assessed the risk of bias from concealment of allocation as low if neither the participants or trial investigators could foresee the allocation of the participants (e.g. using sealed opaque envelopes); we assessed the risk of bias as unclear if methods were not described; and we assessed the risk of bias as high if alternation or an open allocation schedule was used. </p> </section> <section id="CD004449-sec-0044"> <h5 class="title">Blinding</h5> <p>We assessed the risk of bias from blinding as low if participants, investigators and outcome assessors were blinded (or if any of these were not blinded but outcome assessment was blinded and this was judged not to influence the outcome); we judged the risk of bias as unclear if this issue was not discussed; and we judged the risk of bias to be high if none of the parties involved in the trial were blinded. </p> </section> <section id="CD004449-sec-0045"> <h5 class="title">Incomplete outcome data</h5> <p>We judged the risk of bias to be low if any withdrawals were described in full and were equal across groups; we judged the risk of bias to be unclear if insufficient information was given; and we judged the risk of bias to be high if the missing data were likely to be directly related to the outcome or if they were uneven across groups. </p> </section> </section> <section id="CD004449-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcome measures, we sought data on the number of participants with each outcome event, by allocated treated group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow‐up. We aimed to calculate a pooled estimate of the treatment effect for each outcome across studies using the odds ratio (OR) (the odds of an outcome among treatment allocated participants to the corresponding odds among controls). </p> <p>For continuous outcomes, we recorded either mean change from baseline for each group or mean post‐treatment or intervention values and standard deviation (SD) for each group. Then, where appropriate, we planned to calculate a pooled estimate of treatment effect by calculating the mean difference (MD). If different scales had been used for the same outcome we would have considered using the standardised mean difference (SMD). </p> </section> <section id="CD004449-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>As we expected to find cross‐over trials, we decided to analyse cross‐over trials with the marginal probabilities of success method, as described by Elbourne, (<a href="./references#CD004449-bbs2-0017" title="BeckerMP , BalagtasCC . Marginal modelling of binary cross‐over data. Biometrics1993;49(4):997‐1009. ">Becker 1993</a>; <a href="./references#CD004449-bbs2-0020" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analysis involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>) rather than examining them as a parallel trial. Analysing cross‐over trials in this way has been reported to avoid the problem of losing the advantage arising from cross‐over trials (<a href="./references#CD004449-bbs2-0020" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analysis involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). </p> </section> <section id="CD004449-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We sought the necessary data from the original investigators if reports were incomplete. This refers particularly to the data needed to apply the marginal probabilities method to cross‐over trials (<a href="./references#CD004449-bbs2-0017" title="BeckerMP , BalagtasCC . Marginal modelling of binary cross‐over data. Biometrics1993;49(4):997‐1009. ">Becker 1993</a>; <a href="./references#CD004449-bbs2-0020" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analysis involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). </p> </section> <section id="CD004449-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to test heterogeneity between trial results using a standard Chi<sup>2</sup> test and the I<sup>2</sup> statistic using the following cut‐off values (<a href="./references#CD004449-bbs2-0025" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. British Medical Journal2003;327(7414):557‐60. ">Higgins 2003</a>): </p> <p> <ul id="CD004449-list-0005"> <li> <p>not important heterogeneity: 0% to 40%;</p> </li> <li> <p>moderate heterogeneity: 30% to 60%;</p> </li> <li> <p>substantial heterogeneity: 50% to 90%;</p> </li> <li> <p>considerable heterogeneity: 75% to 100%.</p> </li> </ul> </p> </section> <section id="CD004449-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias by visual inspection of the funnel plot, and to investigate outcome reporting bias by comparing trial protocols and results from final papers, or (if protocols are not available) the methods and results sections of final papers. </p> </section> <section id="CD004449-sec-0051"> <h4 class="title">Data synthesis</h4> <p>For the meta‐analysis we planned to use a fixed‐effect model unless we found moderate or significant heterogeneity, in which case we planned to use a random‐effects model. </p> </section> <section id="CD004449-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we had identified moderate or significant heterogeneity, we planned to investigate this by subgroup analysis based on the level of the inhibitor (<a href="./references#CD004449-bbs2-0023" title="HayCRM , BaglinTP , CollinsPW , HillFGH , KeelingDM . The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). British Journal of Haematology2000;111(1):78‐90. ">Hay 2000</a>): </p> <p> <ol id="CD004449-list-0006"> <li> <p>levels of 5 Bethesda units per millilitre (BU/ml) or less;</p> </li> <li> <p>levels in excess of 5 BU/ml.</p> </li> </ol> </p> </section> <section id="CD004449-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform a sensitivity analysis based on the generation of the allocation sequence within the trials, including and excluding quasi‐randomised trials. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004449-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004449-sec-0054"></div> <section id="CD004449-sec-0055"> <h3 class="title">Description of studies</h3> <section id="CD004449-sec-0056"> <h4 class="title">Results of the search</h4> <p>A total of 15 studies were identified by the searches (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>; <a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>; <a href="./references#CD004449-bbs2-0003" title="ChuansumritA , IsarangkuraP , AngchaisuksiriP , SriudompornN , TanpowpongK , HathiratP , et al. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Haemophilia2000;6(2):61‐5. ">Chuansumrit 2000</a>; <a href="./references#CD004449-bbs2-0004" title="dePaulaEV , KavakliK , MahlanguJ , AyobY , LentzSR , MorfiniM , et al. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. Journal of Thrombosis and Haemostasis2012;10(1):81‐9. ">de Paula 2012</a>; <a href="./references#CD004449-bbs2-0005" title="KavakliK , MakrisM , ZulfikarB , ErhardtsenE , AbramsZS , KentG . Home treatment of haemarthroses using a single dose regimen of recombinant activated factor seven in patients with haemophilia and inhibitors. A multi‐center, randomized, double‐blind, cross‐over trial. Thrombosis and Haemostasis2006;95(4):600‐5. ">Kavakli 2006</a>; <a href="./references#CD004449-bbs2-0006" title="LjungR , KarimFA , SaxenaK , SuzukiT , ArkhammarP , RosholmA , et al. 40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis2013;11(7):1260‐8. ">Ljung 2013</a>; <a href="./references#CD004449-bbs2-0007" title="LusherJM , RobertsHR , DavignonG , JoistJH , SmithH , ShapiroA , et al. A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia1998;4(6):790‐8. ">Lusher 1998</a>; <a href="./references#CD004449-bbs2-0008" title="MahlanguJN , CoetzeeMJ , LaffanM , WindygaJ , YeeTT , SchroederJ , et al. Phase I, randomized, double‐blind, placebo‐controlled, single‐dose escalation study of the recombinant factor VIIa variant BAY 86‐6150 in hemophilia. Journal of Thrombosis and Haemostasis2012;10(5):773‐80. ">Mahlangu 2012</a>; <a href="./references#CD004449-bbs2-0009" title="NCT00108758 . Exploratory, multicenter, randomized, double‐blind, uncontrolled trial evaluating the efficacy of activated rFVII (Novoseven) in secondary bleeding prophylaxis in congenital hemophilia A or B patients with inhibitors. clinicaltrials.gov/show/ NCT00108758 (accessed 23 October 2013). ">NCT00108758</a>; <a href="./references#CD004449-bbs2-0010" title="NCT01561391 . Safety and efficacy of activated human recombinant FVIIa in patients with inhibitors during and after major surgery. clinicaltrials.gov/show/NCT01561391(accessed 5 December 2012) (accessed 5 December 2012). ">NCT01561391</a>; <a href="./references#CD004449-bbs2-0011" title="PruthiRK , Matthew P. ValentinoLA , SumnerMJ , SeremetisS , HootsWK . Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open label, randomized multicenter trial. Thrombosis and Haemostasis2007;98(4):726‐32. ">Pruthi 2007</a>; <a href="./references#CD004449-bbs2-0012" title="SantagostinoE , MancusoME , RocinoA , MancusoG , ScaraggiF , MannucciPM . A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. Journal of Thrombosis and Haemostasis2006;4(2):367‐71. ">Santagostino 2006</a>; <a href="./references#CD004449-bbs2-0013" title="SeremetisSV . The clinical use of factor VIIa in the treatment of factor VIII inhibitor patients. Seminars in Hematology1994;31(2 Suppl 4):53‐5. ">Seremetis 1994</a>; <a href="./references#CD004449-bbs2-0014" title="CooperHA , GilchristGS , HootsWK , ShapiroA . Comparison of two doses of recombinant factor VIIa for producing hemostasis during and after surgery in patients with hemophilia A or B and inhibitors and patients with acquired inhibitors. [abstract]. Blood1997;90(10 Suppl 1 Pt 1):600a. CooperHA , HootsWK , ShapiroA . Comparison of two doses of recombinant factor Vlla (rFVlla) for producing hemostasis during and after surgery in patients (PTS) with hemophilia A or B and inhibitors and PTS with acquired inhibitors [abstract]. Thrombosis and Haemostasis1997;Suppl:167‐8. ShapiroAD , GilchristGS , HootsWK , CooperHA , GastineauDA . Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thrombosis and Haemostasis1998;80(5):773‐8. ">Shapiro 1998</a>; <a href="./references#CD004449-bbs2-0015" title="VillarA , AronisS , MorfiniM , SantagostinoE , AuerswaldG , ThomsenHF , et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia2004;10(4):352‐9. ">Villar 2004</a>) and two of these were eligible for inclusion in this review (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>; <a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). The reasons for excluding the 13 studies are summarized below (<a href="./references#CD004449-sec-0097" title="">Characteristics of excluded studies</a>). </p> </section> <section id="CD004449-sec-0057"> <h4 class="title">Included studies</h4> <section id="CD004449-sec-0058"> <h5 class="title">Trial design</h5> <p>Both of the included trials were multicentre cross‐over RCTs. One trial had two arms (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>) and the second trial had three arms (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>)<i>.</i> For the comparison we are evaluating (rFVIIa versus aPCC) the trials were unblinded. </p> </section> <section id="CD004449-sec-0059"> <h5 class="title">Participants</h5> <p>Participants in both trials included adults and children with severe haemophilia with inhibitors (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a><i>;</i><a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). The Astermark trial only included participants with haemophilia A; the Young trial included participants with both haemophilia A and B and did not separately specify the numbers of each. </p> <p>The Astermak trial enrolled 66 participants; however, 14 withdrew prior to treatment or were treated only once. Diaries for a further four participants were not completed (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). The Young trial randomised 42 participants, with 21 completing all three treatment arms. </p> </section> <section id="CD004449-sec-0060"> <h5 class="title">Interventions</h5> <p>Both the included trials compared rFVIIa with aPCC.</p> <p>In the Young trial, rFVIIa 90 mcg/kg was given as an intravenous (IV) bolus administered at zero, three and six hours; rFVIIa 270 mcg/kg as single IV bolus (followed by two placebo infusions); and aPCC 75 IU/kg as a single IV bolus (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). Thus, participants were unblinded to the comparison between aPCC and rFVIIa, but were blinded to the dose of rFVIIa (90 mcg/kg x 3 doses versus 270 mcg/kg as a single bolus with two placebo solutions). </p> <p>In the Astermark trial aPCC 75 to 100 IU/kg (target 85 IU/kg) was given as a single IV bolus; rFVIIa 90 to 120 mcg/kg (target 105 mcg/kg) was given as an IV bolus repeated after two hours (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). Both treatments were administered a mean time of two hours after bleeding onset. </p> </section> <section id="CD004449-sec-0061"> <h5 class="title">Outcomes measured</h5> <p>In both the trials, due to the peculiarity of the clinical condition under evaluation, the outcomes were subjective in nature (participant judgement about the efficacy of the treatment, expressed as global evaluation, pain cessation, motility improvement, need for additional treatment). None of the outcomes measures used were common to both trials, and only one of them made assessments about the safety of the treatment (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). The primary and secondary outcomes of the Young trial were the secondary and primary outcomes of this review, respectively (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>)<i>.</i> </p> </section> </section> <section id="CD004449-sec-0062"> <h4 class="title">Excluded studies</h4> <p>Among the excluded trials, two were not RCTs or quasi‐RCTs (<a href="./references#CD004449-bbs2-0003" title="ChuansumritA , IsarangkuraP , AngchaisuksiriP , SriudompornN , TanpowpongK , HathiratP , et al. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Haemophilia2000;6(2):61‐5. ">Chuansumrit 2000</a>; <a href="./references#CD004449-bbs2-0013" title="SeremetisSV . The clinical use of factor VIIa in the treatment of factor VIII inhibitor patients. Seminars in Hematology1994;31(2 Suppl 4):53‐5. ">Seremetis 1994</a>), five were dose‐finding trials, where the comparators were not alternative therapies (<a href="./references#CD004449-bbs2-0007" title="LusherJM , RobertsHR , DavignonG , JoistJH , SmithH , ShapiroA , et al. A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia1998;4(6):790‐8. ">Lusher 1998</a>; <a href="./references#CD004449-bbs2-0014" title="CooperHA , GilchristGS , HootsWK , ShapiroA . Comparison of two doses of recombinant factor VIIa for producing hemostasis during and after surgery in patients with hemophilia A or B and inhibitors and patients with acquired inhibitors. [abstract]. Blood1997;90(10 Suppl 1 Pt 1):600a. CooperHA , HootsWK , ShapiroA . Comparison of two doses of recombinant factor Vlla (rFVlla) for producing hemostasis during and after surgery in patients (PTS) with hemophilia A or B and inhibitors and PTS with acquired inhibitors [abstract]. Thrombosis and Haemostasis1997;Suppl:167‐8. ShapiroAD , GilchristGS , HootsWK , CooperHA , GastineauDA . Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thrombosis and Haemostasis1998;80(5):773‐8. ">Shapiro 1998</a>; <a href="./references#CD004449-bbs2-0015" title="VillarA , AronisS , MorfiniM , SantagostinoE , AuerswaldG , ThomsenHF , et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia2004;10(4):352‐9. ">Villar 2004</a>; <a href="./references#CD004449-bbs2-0008" title="MahlanguJN , CoetzeeMJ , LaffanM , WindygaJ , YeeTT , SchroederJ , et al. Phase I, randomized, double‐blind, placebo‐controlled, single‐dose escalation study of the recombinant factor VIIa variant BAY 86‐6150 in hemophilia. Journal of Thrombosis and Haemostasis2012;10(5):773‐80. ">Mahlangu 2012</a>; <a href="./references#CD004449-bbs2-0004" title="dePaulaEV , KavakliK , MahlanguJ , AyobY , LentzSR , MorfiniM , et al. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. Journal of Thrombosis and Haemostasis2012;10(1):81‐9. ">de Paula 2012</a>); the remaining six were randomised comparisons of different regimens of rFVIIa given to treat bleeding (<a href="./references#CD004449-bbs2-0005" title="KavakliK , MakrisM , ZulfikarB , ErhardtsenE , AbramsZS , KentG . Home treatment of haemarthroses using a single dose regimen of recombinant activated factor seven in patients with haemophilia and inhibitors. A multi‐center, randomized, double‐blind, cross‐over trial. Thrombosis and Haemostasis2006;95(4):600‐5. ">Kavakli 2006</a>; <a href="./references#CD004449-bbs2-0012" title="SantagostinoE , MancusoME , RocinoA , MancusoG , ScaraggiF , MannucciPM . A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. Journal of Thrombosis and Haemostasis2006;4(2):367‐71. ">Santagostino 2006</a>; <a href="./references#CD004449-bbs2-0006" title="LjungR , KarimFA , SaxenaK , SuzukiT , ArkhammarP , RosholmA , et al. 40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis2013;11(7):1260‐8. ">Ljung 2013</a>; <a href="./references#CD004449-bbs2-0009" title="NCT00108758 . Exploratory, multicenter, randomized, double‐blind, uncontrolled trial evaluating the efficacy of activated rFVII (Novoseven) in secondary bleeding prophylaxis in congenital hemophilia A or B patients with inhibitors. clinicaltrials.gov/show/ NCT00108758 (accessed 23 October 2013). ">NCT00108758</a>) or as surgical prophylaxis (<a href="./references#CD004449-bbs2-0011" title="PruthiRK , Matthew P. ValentinoLA , SumnerMJ , SeremetisS , HootsWK . Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open label, randomized multicenter trial. Thrombosis and Haemostasis2007;98(4):726‐32. ">Pruthi 2007</a>; <a href="./references#CD004449-bbs2-0010" title="NCT01561391 . Safety and efficacy of activated human recombinant FVIIa in patients with inhibitors during and after major surgery. clinicaltrials.gov/show/NCT01561391(accessed 5 December 2012) (accessed 5 December 2012). ">NCT01561391</a>). </p> </section> </section> <section id="CD004449-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD004449-sec-0064"> <h4 class="title">Allocation</h4> <section id="CD004449-sec-0065"> <h5 class="title">Generation of randomisation sequence</h5> <p>In one trial randomisation in association with the first bleeding event was performed in a block of participants equally divided into two (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). The method of randomisation for that first event is not given in the paper. In the second trial, six treatment sequences were generated by the permutation of the three dosing regimens (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). The sequences were randomly assigned to the participants. There is no further information about the method of randomisation in the paper. The risk of bias has to be considered unclear in both trials due to lack of details about randomisation sequence generation; furthermore, blocking by two allows the investigator to guess the treatment assigned to the subsequent participant (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). </p> </section> <section id="CD004449-sec-0066"> <h5 class="title">Concealment of allocation</h5> <p>Both trials were open label for the comparison of rFVIIa versus aPCC, which would mean there was sub‐optimal allocation concealment. However, in the Young trial the comparison between the two different rFVIIa regimens did not provide details about randomisation code concealment. We therefore judged one trial to be at a high risk of bias (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>) and one to be at an unclear risk of bias (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). </p> </section> </section> <section id="CD004449-sec-0067"> <h4 class="title">Blinding</h4> <p>One trial was not blinded for physicians and participants because of the major difference between the two products (physical appearance and required volume for injection); outcome assessment was also not blinded (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). In the second trial, participants and clinicians could not be blinded to the comparison between the two rFVIIa treatments and the aPCC treatment due to differences in physical appearance and required volume for injection, but comparison between the two rFVIIa treatments was blinded (three active boluses versus one active and two placebo boluses) (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). Outcome assessment in this trial was blinded. </p> <p>The risk of bias has to be considered high in both trials.</p> </section> <section id="CD004449-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>A total of 48 participants out of 66 completed the Astermark trial protocol for all time points (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). There were 14 participants who withdrew prior to treatment or were treated only once. Reasons for withdrawal included: no bleeding episodes in the study joints or the timing of prophylactic or other infusions prevented participation (six participants); lack of compliance with the protocol (three participants); concern about using a unfamiliar product, or change of mind about participation (two participants); the trial was stopped by the Ministry of Health in one country because the products were not provided free of charge (one participant); no reason was given for the withdrawal of two participants; the diaries of four participants were not adequately completed for inclusion in the analysis. The trial was reported as to be analysed on an intention‐to‐treat basis, but actually appears to be analysed per protocol, we therefore assessed this trial as having a high risk of bias (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). </p> <p>A total of 21 participants out of 42 completed the Young trial protocol (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). Fourteen participants were randomised but not treated; of the remaining 27 participants, six were withdrawn: three of these for non‐compliance; two for study closure; and one because the participant moved to another centre. The trial was prematurely interrupted and analysed per protocol and thus assessed as having a high risk of bias (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). </p> </section> <section id="CD004449-sec-0069"> <h4 class="title">Selective reporting</h4> <p>We were not able to compare the trial protocols and reports for either trial, due to unavailability of the protocols (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>; <a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). No discrepancy was found between the methods and results sections of the reports. The outcomes and timing were those commonly used in the field and pre‐specified as outcome measures for this review. We therefore judge there to be a low risk of bias from selective reporting. </p> </section> <section id="CD004449-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>Only one of the trials had an objective rather than a subjective measure as the principal outcome (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>); and a risk of bias is inherent in the use of any subjective outcomes (participant‐reported measures). The use of analgesics was allowed during both trials, and potentially interfered with subjective pain assessment by the participants. One trial evaluated the distribution of analgesics in the treatment groups (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). The remaining trial tried to adjust for the concomitant use of analgesic drugs (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). A significantly different number of knee (higher in rFVIIa‐treated participants) and elbow (higher in aPCC‐treated participants) bleeding events were recorded in one trial and the analysis technique used to balance for the uneven distribution of knee bleeds is unfair and not sufficiently detailed (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). The Young trial was interrupted by the sponsor for unspecified reasons (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). </p> </section> </section> <section id="CD004449-sec-0071"> <h3 class="title" id="CD004449-sec-0071">Effects of interventions</h3> <p>We are unable to perform any formal meta‐analyses because the two trials did not have any overlapping outcomes amenable for pooling; therefore, we have simply summarized the results of each of the trials. The authors of both trials provided the data needed to perform the marginal probabilities of success method, namely the number of participants in each of the following groups, for all the relevant outcomes at each reported time‐point: success in both treatment phases; failure in both treatment phases; success with rFVIIa; and failure with aPCC; failure with rFVIIa; and success with aPCC. As previously described by Elbourne, analysing cross‐over trials in this way has been reported to avoid the problem of losing the advantage arising from cross‐over trials (<a href="./references#CD004449-bbs2-0017" title="BeckerMP , BalagtasCC . Marginal modelling of binary cross‐over data. Biometrics1993;49(4):997‐1009. ">Becker 1993</a>; <a href="./references#CD004449-bbs2-0020" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analysis involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). This is our primary analysis and results are reported in the forest plots (<a href="./references#CD004449-sec-0085" title="">Data and analyses</a>). We have also reported the outcome effect measures provided in the original trials in additional tables (<a href="#CD004449-tbl-0001">Table 1</a>; <a href="#CD004449-tbl-0002">Table 2</a>; <a href="#CD004449-tbl-0003">Table 3</a>; <a href="#CD004449-tbl-0004">Table 4</a>; <a href="#CD004449-tbl-0005">Table 5</a>). </p> <div class="table" id="CD004449-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">aPCC 75‐100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses ‐ Treatment efficacy judgement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hours (pts number)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90% CI of the difference (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (75.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (60.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.73 to 29.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.482</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (80.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (78.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.42 to 15.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.059</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (80.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (84.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐18.08 to 9.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (95.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (85.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.29 to 20.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.202</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (90.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.13 to 17.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (97.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (85.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05 to 22.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.325</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The table reports the number and % of participants who judged the treatment efficacious for any treatment and any time point. The 90% CIs of the difference test the hypothesis of equivalence between the treatments. When considering the difference at 2 hours, it has to be taken into account that this time point is before the administration of the second rFVIIa bolus. </p> <p>aPCC: activated prothrombin complex concentrates<br/> CI: confidence interval<br/> rFVIIa: recombinant factor VIIa </p> </div> </div> <div class="table" id="CD004449-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">aPCC 75 ‐ 100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses ‐ Bleeding stop</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hours (number of participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90% CI of the difference (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 to 29.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.495</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.73 to 24.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.309</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.92 to 16.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.069</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.75 to 14.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.038</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.45 to 16.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.075</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.48 to 9.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The table reports the number and % of participants who judged the treatment efficacious for any treatment and any time point. The 90% CIs of the difference test the hypothesis of equivalence between the treatments. When considering the difference at 2 hours, it has to be taken into account that this time point is before the administration of the second rFVIIa bolus. </p> <p>aPCC: activated prothrombin complex concentrates<br/> CI: confidence interval<br/> rFVIIa: recombinant factor VIIa </p> </div> </div> <div class="table" id="CD004449-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses ‐ Pain scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 270 mcg/kg</b> </p> <p><b>(N = 24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 90 mcg/kg x 3</b> </p> <p><b>(n = 22)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC 75 IU/kg</b> </p> <p><b>(n = 22)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positive treatment response (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.3</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The response was globally evaluated 9 hours after treatment. The positive response were defined as at least 3 positive assessments at 1, 3, 6 and 9 hours. The positive assessment was defined on the base of a 3‐level scale (more pain, no difference, less pain). There were no statistically significant differences between treatments (P = 0.219). </p> <p>aPCC: activated prothrombin complex concentrates<br/> rFVIIa: recombinant factor VIIa </p> </div> </div> <div class="table" id="CD004449-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses ‐ Mobility scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 270 mcg/kg</b> </p> <p><b>(N = 24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 90 mcg/kg x 3</b> </p> <p><b>(n = 22)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC 75 IU/kg</b> </p> <p><b>(n = 22)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positive treatment response (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.7</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The response was globally evaluated 9 hours after treatment. The positive response were defined as at least 3 positive assessments at 1, 3, 6 and 9 hours. The positive assessment was defined on the base of a 3‐level scale (more mobility, no difference, less mobility). There were no statistically significant differences between treatments (P = 0.903). </p> <p>aPCC: activated prothrombin complex concentrates<br/> rFVIIa: recombinant factor VIIa </p> </div> </div> <div class="table" id="CD004449-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses ‐ Rescue medication use</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 270 mcg/kg</b> </p> <p><b>(n = 24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 90 mcg/kg x 3</b> </p> <p><b>(n = 22)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC 75 IU/kg</b> </p> <p><b>(n = 22)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants requiring rescue medication n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (9.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (36.4)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Participants with an insufficient treatment response within 6 hours of the first treatment administration were evaluated in the clinic or by phone to consider the use of rescue medication. Rescue medication was defined as additional haemostatic treatment within 9 hours post first administration of trial product. The difference between rFVIIa 270 mcg/kg vs aPCC was statistically significant (P = 0.032). The efficacy difference between the aPCC treatment group and the rFVIIa 90 x 3 mcg/kg did not reach statistical difference (P = 0.069). </p> <p>aPCC: activated prothrombin complex concentrates<br/> rFVIIa: recombinant factor VIIa </p> </div> </div> <section id="CD004449-sec-0072"> <h4 class="title">Primary outcomes</h4> <section id="CD004449-sec-0073"> <h5 class="title">1. Early cessation of bleeding</h5> <section id="CD004449-sec-0074"> <h6 class="title">a. changes on any subjective or objective pain and mobility scale</h6> <p>The primary outcome of the Astermark trial was evaluation of haemostatic effect at six hours following treatment (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). An effective response was defined by creating a dichotomy of the effective and partially effective response versus poorly effective and not effective. Full details of the results analyzed with the marginal probabilities method (<a href="./references#CD004449-bbs2-0017" title="BeckerMP , BalagtasCC . Marginal modelling of binary cross‐over data. Biometrics1993;49(4):997‐1009. ">Becker 1993</a>) for this outcome are presented (<a href="./references#CD004449-fig-0001" title="">Analysis 1.1</a>). A secondary outcome of the Astermark trial, not included in our protocol, is also reported in the additional tables (<a href="#CD004449-tbl-0002">Table 2</a>). </p> <p>The main outcome of the Young trial was an algorithm taking into account pain and mobility scores, and it did not find any significant difference between the treatment groups (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>) (<a href="#CD004449-tbl-0003">Table 3</a>; <a href="#CD004449-tbl-0004">Table 4</a>). This algorithm has not, as yet, been formally validated. The marginal probability score (<a href="./references#CD004449-bbs2-0017" title="BeckerMP , BalagtasCC . Marginal modelling of binary cross‐over data. Biometrics1993;49(4):997‐1009. ">Becker 1993</a>) was recalculated separately for mobility and pain for the assessments at one, three, six and nine hours (<a href="./references#CD004449-fig-0002" title="">Analysis 2.1</a>; <a href="./references#CD004449-fig-0003" title="">Analysis 2.2</a>; <a href="./references#CD004449-fig-0005" title="">Analysis 3.1</a>; <a href="./references#CD004449-fig-0006" title="">Analysis 3.2</a>; <a href="./references#CD004449-fig-0008" title="">Analysis 4.1</a>; <a href="./references#CD004449-fig-0009" title="">Analysis 4.2</a>). The number of participants requiring analgesic drugs was not significantly different among the treatment groups (<a href="./references#CD004449-fig-0004" title="">Analysis 2.3</a>; <a href="./references#CD004449-fig-0007" title="">Analysis 3.3</a>; <a href="./references#CD004449-fig-0010" title="">Analysis 4.3</a>). </p> </section> <section id="CD004449-sec-0075"> <h6 class="title">b. changes in the volume of haematoma assessed radiologically at any point in the first 48 hours </h6> <p>This outcome has not been assessed by either trial.</p> </section> </section> </section> <section id="CD004449-sec-0076"> <h4 class="title">Secondary outcomes</h4> <section id="CD004449-sec-0077"> <h5 class="title">1. Number of participants requiring additional or alternative treatment</h5> <p>In the Astermark trial additional doses were administered in cases where the protocol treatment regimen was not sufficient (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). The timing of the additional doses varied. A small number (two) were administered within the first six hours after onset of treatment. The remainder during the balance of the 48‐hour observation period (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). </p> <p>In the Young trial, participants with an insufficient treatment response within six hours of the first treatment administration were evaluated in the clinic or by telephone to consider the use of rescue medication (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). Rescue medication was defined as additional haemostatic treatment within nine hours after the first administration of trial product. A total of eight bleeding episodes for aPCC, two for rFVIIa 270 mcg/kg and two for rFVIIa 90 mcg/kg x 3 doses required additional medication. The difference between rFVIIa 270 mcg/kg versus aPCC was statistically significant (P = 0.032). The efficacy difference between the aPCC treatment group and the rFVIIa 90 mcg/kg x 3 doses did not reach statistical difference (P = 0.069). Full details of the results about this outcome were provided in the additional tables (<a href="#CD004449-tbl-0005">Table 5</a>). </p> </section> <section id="CD004449-sec-0078"> <h5 class="title">2. Number of participants with adverse effects (thromboses; allergic reactions)</h5> <p>The Astermark trial did not report any trial‐related or drug‐related adverse effects (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>). </p> <p>The Young trial did not report any thrombotic, fatal or clinical laboratory adverse events; however, it did record 32 treatment emergent adverse events in 14 participants. Of these three were in the rFVIIa 270 mcg/kg group, five were in the rFVIIa 90 mcg/kg x 3 doses group and six were in the aPCC group. None were considered to be related to the trial drug (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). </p> </section> <section id="CD004449-sec-0079"> <h5 class="title">3. Correction of abnormal haemostatic laboratory test results</h5> <p>This outcome has not been assessed in either trial. It has to be noted that no commonly available test exists to monitor the effect of by‐passing agents (both aPCC and rFVIIa). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004449-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004449-sec-0080"></div> <p>Since the previous version of this review (<a href="./references#CD004449-bbs2-0036" title="IorioA , MatinoD , D'AmicoR , MakrisM . Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database of Systematic Reviews2010, Issue 8. [DOI: 10.1002/14651858.CD004449.pub3] ">Iorio 2010</a>), 18 new potentially relevant references were found. Five trials were added to the excluded studies list and we did not find any further eligible trials. Therefore, results presented in this update continue to refer to the two trials already included in the 2010 version of this review (<a href="./references#CD004449-bbs2-0036" title="IorioA , MatinoD , D'AmicoR , MakrisM . Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database of Systematic Reviews2010, Issue 8. [DOI: 10.1002/14651858.CD004449.pub3] ">Iorio 2010</a>). However, we were successful in obtaining additional data enabling us to perform the marginal probabilities analysis, although data were still not combined in a formal meta‐analysis (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>; <a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). The new data allowed us to report odds ratios (OR) and to take into account information provided by both treatment periods in the cross‐over trials. There is no change in statistical non‐significance of the results. Overall, both the included trials showed methodological flaws. Both the treatments were shown to be effective and safe and can be used to treat bleeding in people with haemophilia with inhibitors, but were not able to prove superiority of one treatment over the other. It is to be noted that the Astermark trial was designed and analysed as a equivalence trial (<a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a>); the Young trial was aimed at comparing two different dosages of recombinant factor VIIa (rFVIIa) and used activated prothrombin complex concentrates (aPCC) as a reference, without pre‐stating any equivalence range (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). The high number of dropouts in both trials is an important limitation. These data do not show whether the treatments were equivalent or whether one is superior to the other. Due to the widespread use in clinical practice of both by‐passing agents, their efficacy was considered as already proven, and no placebo group was felt to be needed. A significant percentage of dropouts was recorded in both trials, and the Young trial was prematurely discontinued (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). We would like to highlight that we found a relevant difference in treatment efficacy independent of the drug used, i.e. aPCC or rFVIIa, among the two trials (median efficacy of 80% at six hours in the Astermark trial and 40% in the Young trial); this means that both trials showed similar effectiveness of treatment. The difference in median efficacy rates is likely to be related to the subjective nature of the outcome measures or trial protocols or both. With regards to outcome assessment, it is important to note that no objective method is fully validated as far as joint bleeding is concerned. Similarly, there is no general consensus on when assessing the anti‐haemorrhagic effect. The two trials used different scales and assessment times, and in particular the Young trial used a composite algorithm to give an overall judgement of the participants response over a wide range of assessment times (<a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a>). How easily the results of the trials included in the present review can be reproduced in different contexts is hard to say. </p> <p>Based on the available randomised evidence, it is not possible to consider one treatment more efficacious or safer than the other. Other systematic reviews may help in the choice of the more effective concentrates by reviewing non‐randomised evidence (<a href="./references#CD004449-bbs2-0028" title="Lloyd JonesM , WightJ , PaisleyS , KnightC . Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia2003;9(4):464‐520. ">Lloyd Jones 2003</a>); or by using a Bayesian approach to pool randomised and non‐randomised evidence (<a href="./references#CD004449-bbs2-0032" title="TreurMJ , McCrackenF , HeegB , JoshiAV , BottemanMF , DeCharroF , et al. Efficacy of recombinant activated factor seven vs activated prothrombin complex concentrates for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta‐regression. Haemophilia2009;15(2):420‐36. [DOI: 10.1111/j.1365‐2516.2008.01956.x] ">Treur 2009</a>); or by focusing on economical aspects (<a href="./references#CD004449-bbs2-0026" title="KnightC , DanoAM , Kennedy‐MartinT . A systematic review of the cost‐effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia2009;15(2):405‐19. [DOI: 10.1111/j.1365‐2516.2008.01969.x] ">Knight 2009</a>). Another potentially relevant issue, not considered in this systematic review, is that of viral safety of the concentrates under evaluation. The general considerations about the safety of recombinant and plasma‐derived factor VIII and IX concentrates might apply also to bypassing agents (rFVIIa and aPCC). Another aspect to be taken into account is that aPCC contains traces of factor VIII and could possibly induce an anamnestic response to be potentially avoided in patients candidate to immunotolerance treatment. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD004449-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 aPCC 75 ‐ 100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses, Outcome 1 Treatment efficacy judgement." data-id="CD004449-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 aPCC 75 ‐ 100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses, Outcome 1 Treatment efficacy judgement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004449-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses, Outcome 1 Mobility evaluation." data-id="CD004449-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses, Outcome 1 Mobility evaluation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004449-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses, Outcome 2 Pain evaluation." data-id="CD004449-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses, Outcome 2 Pain evaluation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004449-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses, Outcome 3 Need for rescue medication." data-id="CD004449-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses, Outcome 3 Need for rescue medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004449-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 rFVIIa 270 ug/kg vs APCC 75 U/kg, Outcome 1 Mobility evaluation." data-id="CD004449-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 rFVIIa 270 ug/kg vs APCC 75 U/kg, Outcome 1 Mobility evaluation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004449-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 rFVIIa 270 ug/kg vs APCC 75 U/kg, Outcome 2 Pain evaluation." data-id="CD004449-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 rFVIIa 270 ug/kg vs APCC 75 U/kg, Outcome 2 Pain evaluation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004449-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 rFVIIa 270 ug/kg vs APCC 75 U/kg, Outcome 3 Need for rescue medication." data-id="CD004449-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 rFVIIa 270 ug/kg vs APCC 75 U/kg, Outcome 3 Need for rescue medication.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004449-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg, Outcome 1 Mobility evaluation." data-id="CD004449-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg, Outcome 1 Mobility evaluation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004449-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg, Outcome 2 Pain evaluation." data-id="CD004449-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg, Outcome 2 Pain evaluation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004449-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/urn:x-wiley:14651858:media:CD004449:CD004449-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_t/tCD004449-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg, Outcome 3 Need for rescue medication." data-id="CD004449-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg, Outcome 3 Need for rescue medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/media/CDSR/CD004449/image_n/nCD004449-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD004449-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">aPCC 75‐100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses ‐ Treatment efficacy judgement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hours (pts number)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90% CI of the difference (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (75.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (60.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.73 to 29.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.482</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (80.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (78.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.42 to 15.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.059</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (80.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (84.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐18.08 to 9.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (95.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (85.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.29 to 20.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.202</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (90.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.13 to 17.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (97.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (85.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05 to 22.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.325</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>The table reports the number and % of participants who judged the treatment efficacious for any treatment and any time point. The 90% CIs of the difference test the hypothesis of equivalence between the treatments. When considering the difference at 2 hours, it has to be taken into account that this time point is before the administration of the second rFVIIa bolus. </p> <p>aPCC: activated prothrombin complex concentrates<br/> CI: confidence interval<br/> rFVIIa: recombinant factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">aPCC 75‐100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses ‐ Treatment efficacy judgement</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004449-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">aPCC 75 ‐ 100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses ‐ Bleeding stop</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hours (number of participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90% CI of the difference (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD004449-bbs2-0001" title="AstermarkJ , DonfiledSM , DiMicheleDM , GringeriA , GilbertSA , WatersJ , et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood2007;109(2):546‐51. CarllsonKS , AstermarkJ , DonfieldSM , BerntorpE . Health‐Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor ‐ the FEIBA NovoSeven comparative study (FENOC). Blood2006;108:457. ">Astermark 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 to 29.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.495</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.73 to 24.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.309</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.92 to 16.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.069</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.75 to 14.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.038</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.45 to 16.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.075</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.48 to 9.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>The table reports the number and % of participants who judged the treatment efficacious for any treatment and any time point. The 90% CIs of the difference test the hypothesis of equivalence between the treatments. When considering the difference at 2 hours, it has to be taken into account that this time point is before the administration of the second rFVIIa bolus. </p> <p>aPCC: activated prothrombin complex concentrates<br/> CI: confidence interval<br/> rFVIIa: recombinant factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">aPCC 75 ‐ 100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses ‐ Bleeding stop</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004449-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses ‐ Pain scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 270 mcg/kg</b> </p> <p><b>(N = 24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 90 mcg/kg x 3</b> </p> <p><b>(n = 22)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC 75 IU/kg</b> </p> <p><b>(n = 22)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positive treatment response (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.3</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>The response was globally evaluated 9 hours after treatment. The positive response were defined as at least 3 positive assessments at 1, 3, 6 and 9 hours. The positive assessment was defined on the base of a 3‐level scale (more pain, no difference, less pain). There were no statistically significant differences between treatments (P = 0.219). </p> <p>aPCC: activated prothrombin complex concentrates<br/> rFVIIa: recombinant factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses ‐ Pain scale</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004449-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses ‐ Mobility scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 270 mcg/kg</b> </p> <p><b>(N = 24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 90 mcg/kg x 3</b> </p> <p><b>(n = 22)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC 75 IU/kg</b> </p> <p><b>(n = 22)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positive treatment response (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.7</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>The response was globally evaluated 9 hours after treatment. The positive response were defined as at least 3 positive assessments at 1, 3, 6 and 9 hours. The positive assessment was defined on the base of a 3‐level scale (more mobility, no difference, less mobility). There were no statistically significant differences between treatments (P = 0.903). </p> <p>aPCC: activated prothrombin complex concentrates<br/> rFVIIa: recombinant factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses ‐ Mobility scale</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004449-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses ‐ Rescue medication use</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 270 mcg/kg</b> </p> <p><b>(n = 24)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rFVIIa 90 mcg/kg x 3</b> </p> <p><b>(n = 22)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>aPCC 75 IU/kg</b> </p> <p><b>(n = 22)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004449-bbs2-0002" title="YoungG , ShafferFE , RojasP , SeremetisS . Single 270 mcg/kg ‐dose rFVIIa versus standard 90 mcg/kg ‐ dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia2008;14(2):287‐94. ">Young 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants requiring rescue medication n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (9.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (36.4)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Participants with an insufficient treatment response within 6 hours of the first treatment administration were evaluated in the clinic or by phone to consider the use of rescue medication. Rescue medication was defined as additional haemostatic treatment within 9 hours post first administration of trial product. The difference between rFVIIa 270 mcg/kg vs aPCC was statistically significant (P = 0.032). The efficacy difference between the aPCC treatment group and the rFVIIa 90 x 3 mcg/kg did not reach statistical difference (P = 0.069). </p> <p>aPCC: activated prothrombin complex concentrates<br/> rFVIIa: recombinant factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses ‐ Rescue medication use</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/full#CD004449-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004449-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">aPCC 75 ‐ 100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Treatment efficacy judgement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 At 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 At 36 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 At 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">aPCC 75 ‐ 100 IU/kg vs rFVIIa 90 ‐ 120 mcg/kg x 2 doses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004449-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mobility evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 At 9 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 At 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 At 9 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Need for rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004449-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">rFVIIa 270 ug/kg vs APCC 75 U/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mobility evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 9 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 At 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 At 9 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Need for rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">rFVIIa 270 ug/kg vs APCC 75 U/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004449-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mobility evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 9 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 1 hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 At 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 At 9 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Need for rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004449.pub4/references#CD004449-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004449.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004449-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004449-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD004449-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004449-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004449\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004449\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004449\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004449\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004449\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004449.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004449.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004449.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004449.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004449.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725576094"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004449.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725576097"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004449.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7e9d6e41f466',t:'MTc0MDcyNTU3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 